PRODUCTION OF SOLUBLE HUMAN T CELL RECEPTOR CHAINS

描述：(改编自申请者摘要)T细胞恶性肿瘤 占所有淋巴瘤的15%，而目前的治疗方法通常不会产生效果 显著的长期缓解。申请者建议治疗T细胞 淋巴瘤通过诱导一种特定的细胞免疫反应而仅“排斥” 某些正在增殖的T细胞。癌症免疫治疗的圣杯是 识别可用于教导免疫的特异性肿瘤标记物 一种在保留其他单元格的同时移除不需要的单元格的系统 完好无损。他们认为，T细胞受体应该作为一种肿瘤标志物 特别是T细胞淋巴瘤。如果有足够数量的可溶性T细胞受体 因此，通过接种疫苗治疗淋巴瘤可能是可行的。 然而，T细胞受体并不是以可溶形式自然表达的。这个 申请人建议通过生产重组可溶性蛋白来解决这一问题 昆虫细胞中的T细胞受体链。在第一阶段，他们将测试 这种治疗方法在动物模型中的可行性。他们会脉搏跳动 自体专业抗原提呈细胞与重组小鼠T细胞 受体β链体外蚂蚁将处理后的细胞转移到小鼠体内 挑战致瘤T细胞系。如果成功，他们将延长他们的 人类T细胞受体第二阶段研究和第三阶段临床试验。 建议的商业应用：不可用

DESCRIPTION: (Adapted from the applicant's abstract) T-cell malignancies account for 15% of all lymphomas and current treatments do not usually yield significant long-term remission. The applicants propose to treat T-cell lymphoma by inducing a specific cellular immune response to "reject" only the certain proliferating T-cells. The Holy Grail of cancer immunotherapy is the identification of specific tumor markers that can be used to teach the immune system to remove the undesired population of cells while leaving other cells intact. They believe that a T-cell receptor should act as a tumor marker for a particular T-cell lymphoma. If sufficient quantities of soluble T-cell receptor were available then treatment of lymphoma by vaccination might be feasible. However, T-cell receptors are not naturally expressed in soluble form. The applicants propose to solve this problem by producing recombinant soluble T-cell receptor chains in insect cells. In Phase I they will test the feasibility of this therapeutic approach in an animal model. They will pulse autologous professional antigen presenting cells with recombinant mouse T-cell receptor beta chain ex vivo ant transfer the treated cells into mice prior to challenge with a tumorigenic T-cell line. If successful, they will extend their studies to human T-cell receptors in Phase II and clinical trials in Phase III. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE